Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., said the FDA has accepted for review the company's biologics license application for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD) and granted the company's request for priority review. The target date for an FDA decision on the VEGF Trap-Eye BLA is Aug. 20.